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Abstract 
Background: Sarcoidosis is an increasingly recognized multi-systemic condition. Cardiac 
sarcoidosis is associated with ventricular arrhythmias and higher mortality rates. Little 
epidemiological data is available regarding the disease and associated ventricular arrhythmias.  
Methods: Data from the National Inpatient Sample (NIS) database 2012–2014, were reviewed. 
Discharges associated with sarcoidosis were identified as the target population using relevant 
ICD-9-CM codes. Primary outcome was a diagnosis of ventricular tachycardia (VT) in the 
sarcoidosis population. Secondary outcomes include rate of ventricular fibrillation (VF) and 
cardiac arrest. Subgroup analyses were performed to examine the association of VT with 
multiple potential confounding clinical variables. 
Results: Of 18,013,878 health encounters, 46,289 (0.26%) subjects had a diagnosis of 
sarcoidosis. VT and VF were more prevalent among patients with sarcoidosis compared to those 
without a diagnosis of sarcoidosis (2.29% vs. 1.22%; p < 0.001 and 0.25% vs. 0.21%; p < 0.001, 
respectively). Sarcoidosis was also associated with a higher prevalence of cardiac arrest (0.72% 
vs. 0.6%; p < 0.001). In unadjusted analyses, all examined comorbidities were significantly more 
common in those with sarcoidosis, including diabetes mellitus (31.6% vs. 21.25%; p < 0.001), 
hypertension (65.2% vs. 51.74%; p < 0.001), chronic kidney disease (21.09% vs. 14.02%; p < 
0.001), heart failure (24.87% vs. 15%; p < 0.001) and acute coronary syndrome (ACS) (4.32% 
vs. 3.35%; p < 0.001). 
Conclusion: The present study showed that sarcoidosis was associated with increased rates of 
ventricular tachyarrhythmia, which can affect the overall disease morbidity and mortality.  
Key words: cardiac sarcoidosis, ventricular tachycardia, ventricular fibrillation, cardiac 
death 
 
 
Introduction  
Sarcoidosis is a multi-system granulomatous disease of unclear etiology with variable 
presentation. The prevalence ranges from 10.9 per 100,000 for whites to 35.5 per 100,000 for 
blacks [1]. The pathological hallmark of the disease is non-caseating granulomas. Cardiac 
sarcoidosis (CS) is increasingly recognized and associated with higher morbidity and mortality 
rates. Studies show a wide range (3.7–54.9%) of cardiac involvement in patients with systemic 
sarcoidosis [2]. 
Conduction abnormalities and arrhythmias are the most common clinical manifestations 
of CS, followed by congestive heart failure (HF) and sudden death [3]. The prevalence of 
specific arrhythmias is as follows: 26–62% atrioventricular block, 0–15% supraventricular 
tachycardia, 2–42% ventricular tachycardia (VT), and 12–65% sudden cardiac death [4]. Given 
the very rare nature of CS, electrophysiologists rely on small observational studies. It is  
hypothesized herein, that CS could be a significant independent predictor for development of 
VT. The National Inpatient Sample (NIS) was analyzed to test this possibility.  
 
Methods 
Study design and data source  
Data from the NIS database, part of the Healthcare Cost and Utilization Project (HCUP), 
an Agency for Healthcare Research and Quality (AHRQ) was used. This is the largest inpatient 
healthcare database available to the public in the United States of America. The study utilized 
data for the years from 2012 to 2014. The NIS includes a 20-percent stratified sample of all 
discharges from U.S. hospitals participating in the HCUP, approximately 7–8 million discharges 
per year, excluding rehabilitation and long-term acute care hospitals. It contains variables 
extracted from hospital discharge records, including demographic characteristics, principal 
diagnosis, secondary diagnoses or comorbidities, insurance, cost and the procedures performed. 
The database allows for calculating national estimates by providing a “weight” variable [5]. 
When the data expands to estimate nation-wide discharges, it provides estimates corresponding 
to about 38 million annual hospitalizations or 97% of discharges nationwide [6]. Estimates from 
the NIS have been validated against the Centers for Medicare and Medicaid Services registry [5, 
7]. Each discharge record was treated as an individual database entry. The databases used 
International Classification of Diseases-9th Edition (ICD-9) codes to identify diagnoses and 
procedures. 
 
Subjects and variables  
The study population was derived from 18,013,878 hospital discharges available in the 
NIS. Patients with VT and sarcoidosis were identified using ICD-9 codes, 427.1 and 135, 
respectively. Primary outcome was a diagnosis of VT in the sarcoidosis population. Secondary 
outcomes include rate of ventricular fibrillation (VF) and cardiac arrest. Analyses of clinical 
variables were performed to examine the association of VT with multiple confounding factors. 
Confounding variables were identified using the ICD-9 diagnosis codes including both 
patient and hospital level variables, in addition to data year. Patient characteristics included age, 
gender, diabetes mellitus, HF, hypertension, ACS (during the same hospitalization) and chronic 
kidney disease. 
 
Statistical analysis 
Normally distributed continuous variables were expressed as means ± standard deviation 
and compared using the Student t-test. Continuous variables that were not normally distributed 
were expressed as medians with interquartile ranges and compared using Mann-Whitney test. 
Categorical variables were compared using the χ2 test. In order to adjust for potential 
confounders, multivariable logistic regression was performed.  
A median Charlson-Deyo Index (CDI) was calculated for both sarcoidosis and non-
sarcoidosis groups. CDI is a validated measure of comorbidities for administrative data [8]. All 
analyses were performed using STATA 2015 TX: Stata Corp LP. Two-tailed p-value < 0.05 was 
considered statistically significant. 
 
Results  
18,013,878 health encounters were identified from the NIS that represent hospitalizations 
from 2012 to 2014. Of these, 46,289 (0.26%) subjects had a diagnosis of sarcoidosis, and the 
remaining 17,967,589 (99.7%) do not have sarcoidosis among their discharge diagnoses. 
Baseline characteristics of patients with and without sarcoidosis diagnosis are shown in Table 1.  
In unadjusted analyses, patients with sarcoidosis were middle-aged (mean 58.2 ± 13.6 
years) and predominantly female (64.2%). All examined comorbidities were significantly more 
common in those with sarcoidosis, including diabetes mellitus (31.6% vs. 21.25%; p < 0.001), 
hypertension (65.2% vs. 51.74%; p < 0.001), chronic kidney disease (21.09% vs. 14.02%; p < 
0.001), HF (24.87% vs. 15%; p < 0.001) and ACS (4.32% vs. 3.35%; p < 0.001).  
The CDI was 2.3 in the sarcoidosis group vs. 1.7 in the control group. 2.29% (1,059) of 
patients in the sarcoidosis group had a diagnosis of VT vs. 1.22% (218,330) of the control group, 
p < 0.001 (Fig. 1). 
The adjusted odds ratio (OR) of VT in the sarcoidosis group was 1.83 (95% CI 1.72–
1.95; p < 0.001). Table 2 shows independent predictors of VT among CS patients in a 
multivariable analysis. HF (OR 5.24; 95% CI 5.19–5.29; p < 0.001) and ACS (OR 2.84; 95% CI 
2.81–2.87; p < 0.001) were associated with higher OR for VT.  
Ventricular fibrillation was also more common in the sarcoidosis group (0.25% vs. 
0.21%; p < 0.001). The OR of VF in the sarcoidosis group after multivariable logistic regression 
analysis was 1.24 (95% CI 1.03–1.49; p < 0.019; Table 3). Rates of VF was higher with ACS 
(OR 10.45; 95% CI 10.22–10.68; p < 0.001) and HF (OR 3.58; 95% CI 3.50–3.67; p < 0.001).  
Finally, sarcoidosis carries a higher prevalence of cardiac arrest (0.72% vs. 0.6%; p < 
0.001). Cardiac arrest remained more prevalent in sarcoidosis patients (OR 1.21; 95% CI 1.08–
1.35; p < 0.001) as well as ACS 4.91 (95% CI 4.84–4.98; p < 0.001) and HF (OR 2.14; 95% CI 
2.11–2.17; p < 0.001) in multivariable logistic regression analysis as shown in Table 4.  
 
Discussion 
Cardiac involvement in sarcoidosis is associated with increased morbidity and mortality. 
Isolated CS is much more common than suspected; in a retrospective study, 66% of patients with 
CS had disease isolated to the heart [9]. To date, CS has been extremely difficult to diagnose due 
to non-specific clinical manifestations, and the limited sensitivity and specificity of various 
diagnostic modalities [10]. There is also a lack of consensus regarding the diagnostic criteria for 
CS. Ventricular arrhythmias (VT, multifocal or frequent PVCs) are one of the minor criteria of 
the Japanese Ministry of Health and Welfare Criteria for diagnosis of CS, while the HRS 
consensus statement did not include ventricular arrhythmias as a criteria for diagnosing CS [11]. 
The present study analyzed a large database and revealed an increased rate of VT in 
patients with sarcoidosis (2.29%) compared to patients without sarcoidosis (1.22%); p < 0.001. 
HF, hypertension, chronic kidney disease and diabetes mellitus were more common in the 
sarcoidosis group. Even after adjustment for possible biological confounders, the odds for having 
VT was still higher (1.82; 95% CI 1.72–1.95; p < 0.001) in sarcoidosis patients, which suggest 
that CS may be an independent risk factor for VT. 
Other reports suggested VT is the most frequent arrhythmia noted in CS with a reported 
incidence of 23% [12]. ACS and HF are traditional risk factors for development of VT, a fact 
that was confirmed after multivariable logistic regression analyses that showed higher odds of 
VT in ACS and HF population (2.84; 95% CI 2.81–5.87; p < 0.001) and (5.24; 95% CI 5.19–
5.29; p < 0.001), respectively.  
Secondary outcomes of VF and cardiac arrest were both higher in the sarcoidosis group 
(0.25% vs. 0.21%; p < 0.001) and (0.72% vs. 0.6%; p < 0.001), respectively. Moreover, ACS and 
HF were associated with higher cardiac arrest rates (Table 4). This is consistent with a high 
mortality rate in CS seen by Roberts et al. [13], where sudden death was the most common 
manifestation of CS. The present analysis shows increased rates for VF in sarcoidosis patients 
(OR 1.24; 95% CI 1.03–1.49; p < 0.019; Table 3).  
The causality between VT and sarcoidosis cannot be assessed in a retrospective database 
study such as this one. Postulated mechanisms include active inflammation [11], enhanced 
automaticity [12], and ventricular activation and recovery process, which explains the reentry 
mechanism that leads to VT, the most frequent arrhythmia noted in CS [14]. A multicenter 
registry of patents with CS who underwent an EP study showed that the mechanism of VT was 
reentry in virtually all patients [15]. 
Management of arrhythmias in CS is difficult, and effective control of VT is often not 
achievable with a single method therapy. Steroids remain central in the management of CS as it 
can ameliorate cardiac dysfunction [16]. However, recurrent VT may increase with steroid 
therapy as active granulomas are replaced by fibrosis, a substrate for reentrant arrhythmias [17]. 
Corticosteroids have been associated with ventricular aneurysm formation [13], so 
immunosuppressive therapies are recommended in cases of resistant arrhythmias or as a steroid-
sparing strategy [18]. 
Amiodarone and sotalol are widely used to treat VT in patients with CS, although adverse 
reactions may limit their practicality [15]. Amiodarone use may be limited by the incidence of 
pulmonary complications which are often difficult to distinguish from pulmonary sarcoidosis. 
beta-blockers have been shown to increase the incidence of heart block in patients with CS, thus 
limiting the utility of sotalol [14]. 
Prophylactic implantable cardioverter-defibrillator (ICD) placement is recommended for 
patients with sarcoidosis who develop sustained VT or left ventricular systolic dysfunction with 
left ventricular ejection fraction ≤ 35% despite optimal medical therapy and immunosuppression. 
It may also be a reasonable treatment for patients with cardiac sarcoidosis, regardless of their left 
ventricular function, after syncope, near syncope, or inducible VT [11]. ICD placement will 
prevent VT progression but will not prevent recurrence. Therefore, concurrent treatment with 
anti-arrhythmic therapy is necessary in refractory VT [19]. Some experts recommend ICD 
placement in patients with sarcoidosis and non-sustained VT given the high rate of recurrent VT 
despite antiarrhythmic and corticosteroid treatment [10]. 
Radiofrequency ablation is very effective in decreasing or eliminating VT in patients with 
CS according to data from a multicenter registry that showed a 98% reduction in VT burden in 
the first 3 months after ablation [15]. Resistant ventricular tachyarrhythmia and severe 
intractable HF, especially in younger patients, are indications for cardiac transplantation in 
patient with CS [14]. 
 
Study power 
According to available research, this is the largest epidemiological study to assess the 
role of sarcoidosis in VT. Primary analysis confirms an increased rate of VT in sarcoidosis, even 
after adjustment for possible biological confounders. The strength of these findings lies in the 
fact that HCUP is a well-validated database that has been previously utilized in similar research 
studies.  
 
Limitation of the study 
ICD-9 codes were used to identify patient comorbidities. However, prior studies have 
demonstrated that ICD-9 codes exhibit high (> 90%) sensitivity, specificity and positive 
predictive value for cardiovascular disorders such as HF, myocardial infarction and arrhythmias, 
when compared to full medical chart review [7]. Also, due to the nature of the NIS database 
analysis, functional outcomes and long-term data were not available. Moreover, specific 
information regarding medications, electrophysiological studies, or echocardiographic 
parameters were not available. Lastly, due to the observational nature of the study, and 
unmeasured confounding factors may have affected interpretation and causality cannot be 
demonstrated. 
 
Conclusions 
Sarcoidosis carries a risk of various cardiac complications. The present analysis shows 
that hospitalized patients with sarcoidosis have elevated risk of VT, VF, and cardiac arrest.  
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Variables Sarcoidosis 
(n= 46,289) 
No sarcoidosis 
(n= 17,967,589) 
P value 
Age in years, means (SD) 58.2 (+/-13.6) 57.3 (+/-20.6) < 0.001 
Male, % (n) 35.8 (16,556) 40.9 (7,352,675) < 0.001 
Diabetes Mellitus, % (n) 31.60 (14,626) 21.25 (3,818,578) < 0.001 
Hypertension, % (n) 65.20 (30,179) 51.74 (9,297,154) < 0.001 
Chronic kidney disease % (n) 21.09 (9,763) 14.02 (2,519,784) < 0.001 
Acute coronary syndrome, % 
(n) 
3.35 (1,551) 4.32 (777,054) < 0.001 
Heart failure, % (n) 24.87 (11,510) 15.01 (2,696,906) < 0.001 
Charlson-Deyo Index, mean 
(SD) 
2.3 (+/- 2.07) 1.7 (+/- 2.15) < 0.001 
Ventricular tachycardia % (n) 2.29 (1,059) 1.22 (218,330) < 0.001 
Ventricular Fibrillation, % (n) 0.25 (118) 0.21 (38, 012) < 0.001 
Cardiac arrest, % (n) 0.72 (331) 0.60 (108,312) < 0.001 
 
 
 
 
 
Table 1: Baseline variables between the target group 
(Sarcoidosis patients) and the control group  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Odds 
ratio 
 95% Confidence 
Interval  
P value 
Age 1.01 1.013-1.014 < 0.001 
Female 0.44 0.43-0.44 < 0.001 
Sarcoidosis 1.83 1.72-1.95 < 0.001 
Acute coronary syndrome 2.84 2.81-2.87 < 0.001 
Heart failure 5.24 5.19-5.29 < 0.001 
 
 
 
 
 
 
 
 
Table 2: Independent predictors of Ventricular 
Tachycardia  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Odds ratio  95% Confidence  
Interval  
P value 
Age 0.998 0.997-0.999 < 0.001 
Female 0.44 0.43-0.45 < 0.001 
Sarcoidosis 1.24 1.03-1.49 0.019 
Acute coronary syndrome 10.45 10.22-10.68 < 0.001 
Heart failure 3.58 3.50-3.67 < 0.001 
 
 
 
 
 
 
 
 
Table 3: Independent predictors of Ventricular 
Fibrillation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Odds 
ratio 
 95% Confidence 
Interval  
P value 
Age 1.01 1.013-1.014 < 0.001 
Female 0.65 0.65-0.67 < 0.001 
Sarcoidosis 1.21 1.08-1.35 < 0.001 
Acute coronary syndrome 4.91 4.84-4.98 < 0.001 
Heart failure 2.14 2.11-2.17 < 0.001 
 
 
Table 4: Independent predictors of Cardiac Arrest  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 summarises  the outcomes in patient with 
and without Sarcoidosis 
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